EMEA-002516-PIP01-18
Key facts
| Active substance |
Lonafarnib
|
| Therapeutic area |
Other
|
| Decision number |
P/0258/2019
|
| PIP number |
EMEA-002516-PIP01-18
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Eiger BioPharmaceuticals Europe Limited
Tel. +(+1) 877 899 2051 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
| Compliance procedure number |
EMEA-C-002516-PIP01-18
|
| Compliance opinion date |
27/03/2020
|
| Compliance outcome |
positive
|